Eptacog alfa (NovoSeven)
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Severe Postpartum Haemorrhage
Conditions
Severe Postpartum Haemorrhage
Trial Timeline
Aug 26, 2025 → Mar 26, 2027
NCT ID
NCT07157423About Eptacog alfa (NovoSeven)
Eptacog alfa (NovoSeven) is a approved stage product being developed by Novo Nordisk for Severe Postpartum Haemorrhage. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07157423. Target conditions include Severe Postpartum Haemorrhage.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07157423 | Approved | Recruiting |
Competing Products
20 competing products in Severe Postpartum Haemorrhage